Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer
Goff, B.A, Nycum, L.R, Wang, Y, Husain, A, Blank, S.V
Published in Gynecologic oncology (01.06.2014)
Published in Gynecologic oncology (01.06.2014)
Get full text
Journal Article
Efficacy in Patient Subgroups in OCEANS, a Randomized, Double-blinded, Placebo-controlled, Phase 3 Trial of Chemotherapy ± Bevacizumab in Patients with Platinum-sensitive Recurrent Epithelial Ovarian (OC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)
Aghajanian, C, Blank, S.V, Goff, B, Judson, P.L, Makhija, S, Sharma, S.K, Nycum, L.R, Yi, J, Husain, A
Published in European journal of cancer (1990) (2011)
Published in European journal of cancer (1990) (2011)
Get full text
Journal Article
Updated Overall Survival Analysis in Oceans, a Randomized Phase 3 Trial of Gemcitabine (G) + Carboplatin (C) and Bevacizumab (BV) or Placebo (PL) Followed by BV or PL in Platinum-Sensitive Recurrent Epithelial Ovarian (ROC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)
Aghajanian, C., Nycum, L.R., Goff, B., Nguyen, H., Husain, A., Blank, S.V.
Published in Annals of oncology (01.09.2012)
Published in Annals of oncology (01.09.2012)
Get full text
Journal Article
The Role of p27 in Endometrial Carcinoma
Nycum, L.R., Smith, L.M., Farley, J.H., Kost, E.R., Method, M.W., Birrer, M.J.
Published in Gynecologic oncology (01.05.2001)
Published in Gynecologic oncology (01.05.2001)
Get full text
Journal Article